How Oxford Medical Sciences is fighting Coronavirus
Researchers from across the Medical Sciences Division are working hard to combat the COVID-19 crises. With particular strengths in infectious diseases and international health, we are well placed to contribute to better understanding and effectively controlling the epidemic. We have a long history of responding to crises, in the UK and around the world and are leaders in emergency vaccine development. During the 2014 Ebola outbreak, our scientists performed the world’s first human Ebola vaccine studies, starting them before any other university or company. Our researchers, in collaboration with partners across the globe, are working to develop an effective vaccine and drugs to target this virus, and have already introduced innovative public health measures and collaborative online tools that are being used in hospitals here and abroad.
Support our Research
Find out how to support Oxford's coronavirus work across a number of key research areas.
Support our researchers
Opportunities for our researchers and support requests.
Coronavirus-related news from across the Medical Sciences Division
3,400 different medicines used globally to treat COVID-19
11 May 2021
Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study.
Children and Adolescents’ Mental Health: One Year On
10 May 2021
Parents and carers reported that behavioural, emotional and attentional difficulties in their children changed considerably throughout the past year, increasing in times of national lockdown and decreasing as restrictions eased and schools reopened, according to the latest Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) study, led by experts at the University of Oxford.
Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
23 April 2021
COVID-19 infections fell significantly – by 65% - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.
National survey reveals big reductions in COVID-19 infections with single dose of Oxford-AZ and Pfizer vaccines
23 April 2021
Data from the COVID-19 Infection Survey, a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC), is the first to show the impact of vaccination on antibody responses and new infections in a large group of adults from the general population aged 16 years and older.
Research uncovers high risk to pregnant women from COVID-19
23 April 2021
A study of more than 2,100 pregnant women across 18 countries worldwide has revealed that COVID-19 is associated with a higher risk of severe maternal and newborn complications than previously recognised.
COVID-19: does exercising really reduce the risk?
19 April 2021
Human challenge trial launches to study immune response to COVID-19
19 April 2021
Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
Find out how other parts of the University are tackling COVID-19
Researchers across the University of Oxford are at the forefront of global efforts to understand COVID-19 and protect our communities.
Support our Research
Find out how to support Oxford's coronavirus work across a number of key research areas.